CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
DOI 10.1055/s-0031-1285288
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Moehler, A Mueller, JT Hartmann, MP Ebert, SE Al-Batran, P Reimer, M Weihrauch, F Lordick, T Trarbach, S Biesterfeld, M Kabisch, D Wachtlin, PR Galle
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Tumour angiogenesis, growth, and metastasis can be inhibited by blocking receptor tyrosine kinases (RTKs) overexpressed in human advanced gastric cancer (AGC), including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptors (PDGFRs). Sunitinib malate, an oral, multi-targeted tyrosine kinase inhibitor of VEGFR1, -2, and…
Zitieren
Zitierempfehlung
M Moehler, A Mueller, JT Hartmann, MP Ebert, SE Al-Batran, P Reimer, M Weihrauch, F Lordick, T Trarbach, S Biesterfeld, M Kabisch, D Wachtlin, PR Galle (2011) An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0031-1285288
Mit CareLit weiterarbeiten